

In the Specification:

At page 1, in the first sentence following the title, after "This patent application" please insert the text --~~is a continuation application of U.S. Patent Application Serial No. 09/061,400, filed on April 16, 1998 (allowed)~~ which in turn --

At page 7, line 15, please replace "12301 Parklawn Drive, Rockville, MD 20852" with --
10801 University Boulevard Manassas, VA 20110-2209--.

In the Claims:

Please cancel claims 1-47, 49-50, 52-75 and 78-79 without prejudice.

Please add new claims 80-114 as follows:

80. An isolated nucleic acid molecule selected from the group consisting of:

- (a) an isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID No: 1;
- (b) an isolated nucleic acid molecule comprising the nucleotide sequence of the DNA insert of the plasmid deposited with ATCC as Accession Number 98409;
- (c) an isolated nucleic acid molecule which is a unique fragment of the nucleic acid molecule having the nucleotide sequence of SEQ ID No: 1; *(2)*
- (d) at least 50% identical to the nucleotide sequence of SEQ ID No: 1;
- (e) an isolated nucleic acid molecule that hybridizes under stringent conditions to the nucleic acid molecule having the nucleotide sequence of SEQ ID No: 1;
- (f) an isolated nucleic acid molecule which is a degenerate sequence variant of the nucleic acid molecule having the nucleotide sequence of SEQ ID No: 1;
- (g) an isolated nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence of SEQ ID No: 2;

(h) an isolated nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence which is at least 75% identical to the polypeptide having the amino acid sequence of SEQ ID No: 2; and

(i) an isolated nucleic acid molecules which is complementary to the nucleic acid molecule in any of subparts (a), (b) or (e).

81. An oligonucleotide selected from the group consisting of:

(a) an oligonucleotide that hybridizes to a unique fragment of the nucleic acid molecule having the nucleotide sequence of SEQ ID No: 1;

(b) an oligonucleotide that hybridizes to a unique fragment of the nucleic acid molecule having the nucleotide sequence of SEQ ID No: 1 under stringent conditions;

(c) an oligonucleotide that hybridizes to a unique fragment of the nucleic acid molecule having the nucleotide sequence of SEQ ID No: 1 under intracellular conditions;

(d) an oligonucleotide as in subpart (a) comprising at least one modification in a nucleotide base, backbone sugar, phosphate or sugar-phosphate linkage;

(e) an oligonucleotide as in subpart (a) comprising a peptide nucleic acid backbone;

(f) an oligonucleotide as in subpart (a) which is detectably labeled;

(g) an oligonucleotide as in subpart (a) which is biotinylated, radiolabeled or fluorophore-conjugated;

(h) an oligonucleotide as in subpart (a) wherein said unique fragment is at least 9 nucleotides in length;

(i) an oligonucleotide as in subpart (a) wherein said unique fragment is at least 15 nucleotides in length;

(j) an oligonucleotide as in subpart (a) wherein said unique fragment is at least 21 nucleotides in length;

(k) an oligonucleotide as in subpart (a) wherein said unique fragment is a locus comprising a 5' untranslated sequence, transcription initiation site, coding sequence, intron-exon boundary, polyadenylation site, or 3' untranslated sequence in the nucleic acid of SEQ ID No: 1; and

(I) an oligonucleotide having a nucleotide sequence selected from the group consisting of SEQ ID Nos: 4, 5, 6, 7 and 8.

82. An antisense vector comprising the oligonucleotide of claim 81.

83. An antisense pharmaceutical composition comprising the oligonucleotide of claim 81 or a vector of comprising said oligonucleotide, dispersed in a pharmaceutically acceptable vehicle.

84. An isolated MRP- β polypeptide selected from the group consisting of:

- a polypeptide comprising the amino acid sequence of SEQ ID No: 2;
- a polypeptide comprising an amino acid sequence sharing at least 75% sequence identity with the amino acid sequence of SEQ ID No: 2;
- a polypeptide which is an epitope unique to the MRP- β polypeptide having the amino acid sequence of SEQ ID No: 2; and
- the polypeptide as set forth in subpart (c), where said epitope is displayed by a cell expressing an MRP- β gene.

85. An antibody that binds selectively to the polypeptide of claim 84, or an antigen-binding fragment thereof.

86. A fusion polypeptide selected from the group consisting of:

- a fusion polypeptide comprising an antigen-binding fragment of claim 85.
- a fusion polypeptide as set forth in subpart (a) further comprising a cytotoxic polypeptide, such that said fusion polypeptide stimulates cytolysis of a cell expressing an MRP- β gene; and
- a fusion polypeptide as set forth in subpart (a) further comprising a chemoattractant, such that said fusion polypeptide stimulates destruction of a cell expressing an MRP- β gene by macrophages, killer T cells or cytotoxic T cells.

87. An expression vector comprising a nucleic acid molecule encoding the polypeptide of claim 84.

88. A cell selected from the group consisting of:

- (a) a cell transfected with the expression vector of claim 87;
- (b) a cell transfected with the expression vector of claim 87, wherein said cell is immortalized under cell culture conditions;
- (c) a cell as in subpart (b), wherein said cell is of human origin;
- (d) a cell as in subpart (b), wherein said cell is a unicellular organism;
- (e) a cell as in subpart (d), wherein said cell is yeast cell; and
- (f) a cell as in subpart (a), wherein said cell is a non-human mammalian embryonic blastocyst cell.

89. A non-human mammal produced by intrauterine implantation of a blastocyst comprising a cell transfected with an expression vector comprising a nucleic acid molecule encoding the polypeptide of claim 84, wherein said cell is a non-human mammalian embryonic blastocyst cell.

90. A progeny of the mammal of claim 89, said progeny characterized by germline integration of said nucleic acid encoding said polypeptide.

91. A null vector comprising nucleic acid encoding a non-expressible variant of a polypeptide having an amino acid sequence sharing at least 75% sequence identity with the amino acid sequence of SEQ ID No: 2

92. A cell transfected with the null vector of claim 91.

93. The cell of claim 92, wherein said cell is a non-human mammalian embryonic blastocyst cell.

94. A non-human mammal produced by intrauterine implantation of a blastocyst comprising the cell of claim 93.

95. A progeny of the mammal of claim 94, said progeny characterized by germline integration of said nucleic acid molecule.

96. A method of detecting expression of an MRP- β gene, comprising the steps of:

- obtaining cellular tissue from a mammal suspected of harboring cells expressing an MRP- β gene encoding a polypeptide comprising the amino acid sequence of SEQ ID No: 2;
- releasing RNA from said cellular tissue;
- combining, under hybridization conditions, said released RNA with an oligonucleotide that hybridizes to the complement of SEQ ID No: 1 or a unique fragment thereof; and
- assaying said released RNA for formation of a hybrid comprising said oligonucleotide, formation of which indicates that cells of said tissue express said MRP- β gene.

97. The method of claim 48 or 96, wherein said cellular tissue is suspected of comprising transformed cells.

98. The method of claim 48, 51 or 96, wherein said oligonucleotide comprises a peptide nucleic acid backbone.

99. A method of characterizing drug-resistant phenotype of a transformed cell of mammalian origin, comprising the steps of:

- obtaining cellular tissue from a mammal suspected of harboring transformed cells;
- contacting said tissue with an antibody of claim 85, under conditions such that, if cells of said tissue display said an epitope selectively bound by said antibody, an antibody-epitope complex forms; and,
- assaying said tissue for the presence of said complex, formation of which indicates presence of transformed cells having a drug-resistant phenotype in said mammal.

100. The method of claim 51 or 99 wherein said cellular tissue is selected from the group consisting of:

- (a) cellular tissue which is of mammary, respiratory tract, urogenital tract, endocrine system or immune system origin;
- (b) cellular tissue which is of mammary origin and comprises a breast biopsy sample;
- (c) cellular tissue which is of respiratory tract origin and comprises a bronchoalveolar lavage sample;
- (d) cellular tissue which is of urogenital tract origin and comprises an ovarian, uterine or cervical biopsy sample;
- (e) cellular tissue which is of urogenital tract origin and comprises a prostate or testicular biopsy sample;
- (f) cellular tissue which is of endocrine system origin and comprises a pancreatic biopsy sample; and
- (g) cellular tissue which is of immune system origin and comprises a spleen, bone marrow or lymph node biopsy sample.

- 101. A method of mitigating aberrant expression of an MRP- β gene, comprising administering an antisense pharmaceutical composition of claim 83 to a mammal suffering from effects of said aberrant expression, under conditions sufficient to attenuate a phenotype associated therewith.
- 102. A method of mitigating aberrant activity of an MRP- β gene, comprising administering an antisense pharmaceutical composition of claim 83 to a mammal suffering from effects of said aberrant activity, under conditions sufficient to attenuate a phenotype associated therewith.
- 103. A method of improving effectiveness of chemotherapy for a mammal afflicted with a multidrug-resistant tumor, comprising administering a chemotherapeutic drug to said mammal; and coadministering an antisense pharmaceutical composition of claim 83, such that said antisense pharmaceutical composition mitigates resistance of said tumor to said chemotherapeutic drug.
- 104. A method of treating a mammal suffering from aberrant expression of an MRP- β gene or a mammal suffering from aberrant activity of an MRP- β , comprising administering a

fusion polypeptide of claim 86 to said mammal, in an amount effective for destroying cells aberrantly displaying an epitope unique to an MRP- β polypeptide.

Sure
01

105. A method of treating a ~~mammal afflicted with~~ multidrug-resistant tumor, comprising the step of ~~administering~~ a fusion polypeptide of claim 86 to said mammal, in an amount effective for destroying tumor cells displaying an epitope unique to an MRP- β polypeptide.

A12
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

106. A method of identifying a modulator of MRP- β , comprising the steps of:

- contacting a cell transfected with a vector comprising a nucleic acid molecule encoding the polypeptide of claim 84 with a candidate modulator of MRP- β ;
- assaying the level of MRP- β gene expression or MRP- β polypeptide expression in said cell, wherein a detectable fluctuation in said level indicates that said candidate is an MRP- β modulator.

107. A method of identifying a modulator of MRP- β , comprising the steps of:

- contacting a cell transfected with a vector comprising a nucleic acid molecule encoding the polypeptide of claim 84 with a substrate transported by MRP- β ;
- contacting said cell with a candidate modulator of MRP- β ;
- assaying the amount of said substrate exported by said cell, wherein a detectable fluctuation in said amount indicates that said candidate is an MRP- β modulator.

108. A method of identifying a modulator of MRP- β , comprising the steps of:

- contacting a cell transfected with a vector comprising a nucleic acid molecule encoding the polypeptide of claim 84 with a cytotoxin exported or sequestered by MRP- β ;
- contacting said cell with a candidate modulator of MRP- β ;
- assaying survival of said cell, a detectable fluctuation in which indicates that said candidate is an MRP- β modulator.

109. A method of identifying a modulator of MRP- β , comprising the steps of:

1C

1

C

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

<p style